# Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer

> **NCT01288339** · PHASE2 · COMPLETED · sponsor: **Grupo Espanol Multidisciplinario del Cancer Digestivo** · enrollment: 78 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Panitumumab + FOLFOX (DP)
- **DRUG:** Panitumumab + FOLFOX (no-DP)

## Key facts

- **NCT ID:** NCT01288339
- **Lead sponsor:** Grupo Espanol Multidisciplinario del Cancer Digestivo
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11-08
- **Primary completion:** 2015-02-13
- **Final completion:** 2015-02-13
- **Target enrollment:** 78 (ACTUAL)
- **Last updated:** 2018-05-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01288339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01288339, "Study Assessing Potential Predictive Tumor Markers in Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01288339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*